You are attempting to access a website operated by an entity not regulated in the EU. Products and services on this website do not comply with EU laws or ESMA investor-protection standards.
As an EU resident, you cannot proceed to the offshore website.
Please continue on the EU-regulated website to ensure full regulatory protection.
수요일 Jan 3 2024 23:12
4 분
Moderna shares soared over 13% on Tuesday and extended their gains into Wednesday following an "outperform" rating from the investment bank Oppenheimer, which suggested the Covid vaccine producer could introduce five new products to the market by 2026.
Despite a challenging 2023, marked by a substantial decline in demand for Covid-related products, Moderna's stock saw a significant boost with Oppenheimer's upgrade. The pharmaceutical company, heavily reliant on its Covid shot, witnessed a nearly 45% drop in its share price last year.
Moderna rivals such have also suffered from similar factors. The Pfizer share price fell by over 40% over the past year, while BioNTech stock shed over 24.5% of its value and AstraZeneca shares declined by over 7%. Pfizer stock took its latest hit in December, when the New York-based pharma company projected 2024 revenue and profit below Wall Street's expectations due to lower Covid-related revenues.
Oppenheimer analyst Hartaj Singh acknowledged the potential for a dip in Covid sales for Moderna in 2024 due to factors like vaccine fatigue. However, the firm anticipates a resurgence in Covid vaccine sales in 2025 and beyond, fueled by increased awareness and education about the disease.
Singh expressed optimism about Moderna's pipeline, pointing to potential product launches in the next 12 to 18 months that could drive sales in 2025. This includes the potential approval of Moderna's experimental vaccine targeting respiratory syncytial virus (RSV) in older adults. A decision from the U.S. Food and Drug Administration (FDA) is expected in April.
오늘 거래를 개설한 경우 발생할 수 있는 손익(총 비용 및 수수료)을 계산하세요.
시장
상품
계좌 유형
포지션
수량
금액은 다음보다 크거나 같아야 합니다. 기준 금액:
금액은 다음보다 작아야 합니다. 기준 금액:
금액은 최소 랏 증가분의 배수여야 합니다.
USD
EUR
GBP
CAD
AUD
CHF
ZAR
MXN
JPY
가격
수수료
스프레드
레버리지
환전 수수료
유지증거금
오버나이트 스왑
과거의 성과가 미래의 결과를 보장하는 것은 아닙니다.
계좌 통화와 일치하지 않는 통화로 표시된 상품의 포지션을 청산할 경우, 환전 수수료가 부과됩니다.
Singh also highlighted the possibility of FDA approval for Moderna's experimental flu vaccine in 2024 or 2025. Recent trial results indicated a stronger immune response against four flu virus strains compared to currently available vaccines.
The analyst suggested that Moderna also might seek FDA approval for its experimental personalized cancer vaccine in 2024 or 2025. The company could utilize the FDA's accelerated approval pathway, expediting the process for drugs addressing serious conditions with an unmet medical need, based on specific clinical trial metrics.
Moderna and its partner, pharma multinational Merck, are currently conducting studies on the cancer vaccine in conjunction with Merck's Keytruda therapy, targeting patients with melanoma and other cancers.
On Tuesday, Moderna reiterated its anticipation of sales growth in 2025, as outlined in a shareholder letter. The company emphasized the potential approval of its RSV vaccine and a combination shot targeting both Covid and the flu, with the latter possibly receiving approval "as early as 2025."
In its third-quarter earnings release last November, Moderna projected a decline in revenue to $4 billion in 2024 before expecting growth in 2025. The company aims to achieve a "break even" point in 2026. November's announcement also indicated that Moderna was likely to reach the lower end of its sales forecast range of $6 billion to $8 billion for 2023, reflecting diminished demand for Covid vaccines.
Moderna has also expressed its intention to introduce up to 15 products in the next five years — a goal initially outlined during its annual research and development day in September.
According to 16 analysts surveyed by TipRanks that offered 12-month Moderna share price targets, the consensus forecast for MRNA stock stands at $134.07 — a potential 23.15% upside from its current price as of January 3, 2024.
The highest listed Moderna stock price forecast on the platform is $310.00, while the lowest stands at $60. Of the 16 analysts surveyed, 8 offered a Buy rating on Moderna stock, while 6 had it as a Hold, and 2 gave it a Sell.
At the time of writing on Wednesday, Moderna shares, which trade on the Nasdaq stock market under the ticker MRNA, were close to 3.60% down on the day at $108.41, after having closed up over 13% on Tuesday at $112.50.
The MRNA share price was close to 38% down since January 3, 2023.
위험 고지: 본 기사는 저자의 견해만을 반영하며, 정보 제공 목적으로만 작성되었습니다. 이는 투자 조언, 투자 리서치 또는 거래 권유를 구성하지 않으며, Markets.com 플랫폼의 입장을 대변하지도 않습니다. 주식, 지수, 외환(FX), 원자재의 거래 및 가격 예측을 고려할 때, CFD 거래에는 상당한 수준의 위험이 수반되며 모든 투자자에게 적합하지 않을 수 있음을 유의하시기 바랍니다. 레버리지 상품은 원금 손실을 초래할 수 있습니다. 과거의 성과는 미래의 결과를 보장하지 않습니다. 거래 전에 관련된 위험을 완전히 이해하고, 투자 목표와 경험 수준을 고려하십시오. 암호화폐 CFD 및 스프레드 베팅 거래는 모든 영국 소매 고객에게 제한됩니다.
최신
모두 보기토요일, 25 10월 2025
3 분
금요일, 24 10월 2025
4 분
금요일, 24 10월 2025
3 분
KO
